1. Uprety D, Adjei AA. KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020;89:102070.
2.
Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies:
is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533-552. 3.
Hofmann MH, Gerlach D, Misale S, Petronczki M, Kraut N. Expanding the
Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov.
2022;12(4):924-937. 4.
Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to
druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.5.
Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a
Noncovalent, Potent, and Selective KRASG12D Inhibitor. J Med Chem.
2022;65(4):3123-3133 6.
Fang Yang, Yalei Wen, Chaofan Wang, Yuee Zhou, Yang Zhou, Zhi-Min
Zhang, et al. Efficient targeted oncogenic KRAS G12C degradation via
first reversible-covalent PROTAC. Eur J Med Chem. 2022 Feb
15;230:114088.. 7.
James G Christensen Mirati Therapeutics, San Diego. Discovery and
Characterization of MRTX1133, a Selective Non-covalent Inhibitor of
KRASG12D.AACR-NCI-EORTC Virtual International Conference on MOLECULAR
TARGETS Ameri ANDCANCER THERAPEUTICS for Cal FINDING October 7-10, 20218.
Herpers B, Eppink B, James MI, et al. Functional patient-derived
organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5
bispecific antibody with efficacy in epithelial tumors. Nat Cancer. 9.
2022;3(4):418-436. Zhongwei Mao, Hongying Xiao, Panpan Shen, Yu Yang,
et al. KRAS(G12D) can be targeted by potent inhibitors via formation of
salt bridge. Cell Discov. 2022 Jan 25;8(1):5.
